Healthcare
Palatin Technologies, Inc.(PTN)
Live Price
Offline$13.61
-0.51% today
1Y Change
+86.93%
Window
Jun 23, 2025 โ May 29, 2026
- Market Cap
- $530.00M
- Revenue Growth
- -100.0%
- EPS Growth
- -1491.6%
- Dividend Yield
- 0.0%
Coverage: 236 bars ยท Jun 23, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Palatin Technologies, Inc. (PTN) is a Healthcare stock with a market cap of $530.00M and listed on AMEX. The stock last traded around $13.61 and up 86.9% across the available one-year price window (Jun 23, 2025 โ May 29, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -1491.6%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -1491.6%, free cash flow +32.4% with operating margin -134.8% and ROIC -102.3%. Valuation already assumes a fairly strong business story at price/sales 58.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PTN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
-134.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 19, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at -1491.6%, with operating margin around -134.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +48.3% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 19, 2026 | โ | +2.2% | +2.9% | โ |
2026 Feb 17, 2026 | -21.5% | +10.0% | +30.8% | +32.1% |
2025 Nov 14, 2025 | โ | +17.9% | +111.3% | +159.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PTN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PTN Max Drawdown
-71.32%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PTN and SPY.
Company Overview
Palatin Technologies, Inc.
New York Stock Exchange American
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
- Leadership
- Carl Spana
- IPO Date
- Oct 15, 1997
- Employees
- 30
- Street Address
- Cedar Brook Corporate Center
- Mailing
- Cranbury, NJ, 08512
- Region
- Cranbury, NJ, US
- Reporting Currency
- USD
- Investor Line
- 609 495 2200
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 58.7
- Price/Book
- 1.7
Growth
- Revenue
- -100.0%
- EPS
- -1491.6%
- Free Cash Flow
- +32.4%
Profitability
- Gross Margin
- 99.2%
- Operating Margin
- -134.8%
- Net Margin
- -107.4%
- ROE
- -5515.1%
- ROIC
- -102.3%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 2.76
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.